Skip to main content
Premium Trial:

Request an Annual Quote

Microarray Slide Developer Accelr8 Hopes to Close Inaugural Licensing Deals by July

NEW YORK, June 21 - Nascent microarray-slide developer Accelr8 hopes to close "a couple of licensing deals" for its OptArray protein slides in the US, Europe, and Asia before the end of July, a company official told GenomeWeb today.

 

David Howson, director of business development at Accelr8, said the deals are anticipated to close before the end of the firm's fiscal year, which ends on July 31. Citing the beleaguered genomics and biotechnology markets, he added "there's obviously no guarantees" that the agreements will happen.

 

The deals would be the first for the Denver-based company, which began life as a software-development firm but found itself in the protein-slide business after acquiring another firm's technology in early 2001.

 

Its coming out product in the heated array-consumables market is a pair of biotin-coated slides called OptArray. The slides, released in mid-April, are covered with Accelr8's so-called OptiChem coating, which the company claims helps researchers bind probes while eliminating certain non-specific protein absorption without masking or blocking.

 

Howson added that Accelr8, which has nine employees, will announce in 30 days the name of the manufacturing facility that will crank out its chips.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.